Corporate insider profile
Steven Gillis Insider Trades
Steven Gillis has reported 5 open-market purchases on SEC Form 4 and is a net buyer of $87,820,147 across 6 companies. The most recent open-market transaction was reported on Nov 4, 2026. Source: SEC Form 4 filings.
Latest reported as Corporate insider of Lyell Immunopharma, Inc. (LYEL).
SEC-reported filing activity is provided for research purposes and is not investment advice.
- Purchase filings
- 5
- Reported companies
- 6
- Net open-market value
- $87,820,147
- Latest transaction
- Nov 4, 2026
Affiliated corporations
Reported company relationships
LYELLatest reported
Lyell Immunopharma, Inc.
Corporate insider
ASPEPrior filing
Aspen Neuroscience, Inc.
10% Owner
CTYPrior filing
CITY THERAPEUTICS, INC.
Corporate insider
BOLDPrior filing
Boundless Bio, Inc.
Corporate insider
KARDPrior filing
Kardigan, Inc.
Corporate insider
SPTXPrior filing
Seaport Therapeutics, Inc.
10% Owner
Transaction history
Open-market Transactions
Common questions
Steven Gillis insider trading FAQ
- Is Steven Gillis buying or selling stock?
- Across all SEC Form 4 open-market filings on record, Steven Gillis is a net buyer of $87,820,147, with 5 open-market purchases reported. The latest transaction was reported on Nov 4, 2026.
- Which companies does Steven Gillis report insider trades for?
- Steven Gillis has reported open-market trades in Lyell Immunopharma, Inc. (LYEL), Aspen Neuroscience, Inc. (ASPE), CITY THERAPEUTICS, INC. (CTY), Boundless Bio, Inc. (BOLD), Kardigan, Inc. (KARD), and 1 other company. The latest SEC-reported relationship is Corporate insider of Lyell Immunopharma, Inc. (LYEL).
- Where does Steven Gillis's insider trading data come from?
- Watch Insiders reads the SEC Form 4 filings submitted to EDGAR under reporting owner CIK 1229592, and refreshes this page daily.
